Precision BioSciences
NASDAQ: DTILDurham, US · Delaware corporation · 10 known investors
Precision BioSciences is a clinical-stage biotechnology company developing genome-editing therapies based on its ARCUS platform. Note: the page content provided contains only a cookie consent notice, so this description reflects the company's known focus rather than the extracted text.
Founders & leadership
JS
JEFF SMITHExecutive Officer
DJ
DEREK JANTZExecutive Officer, Director
MK
MATTHEW KANEExecutive Officer, Director
TM
TODD MELBYExecutive Officer
BA
BEN AUSPITZDirector
JS
Jeff SmithCo-founder
DJ
Derek JantzCo-founder
RA
ROBERT ADELMANDirector
Investors · 10
age1San Francisco · $500K – $4M
Aliment CapitalLos Angeles · $3M – $5M
Brace PharmaAtlanta
F-Prime Capital PartnersCambridge · $3M – $10M
OCV PartnersLos Angeles
OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
RA CapitalBoston
venBio PartnersSan Franciscovia Robert Adelman · board
Vivo CapitalPalo Alto · $10M – $50M
Agent CapitalreportedWaltham
Reported raises · per SEC filings
Form D private placements▶$39.5MraisedMar 2019 · 23 investors · BiotechnologyRule 506(b)
▶$39.5MraisedMar 2019 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Derek JantzExecutive Officer, Director
- Matthew KaneExecutive Officer, Director
- Robert AdelmanDirector
- Shalini SharpDirector
- Jeff SmithExecutive Officer
- Abid AnsariExecutive Officer
- Tony YaoDirector
- Offering amount
- $70M
- Amount sold
- $39.5M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$88.1MraisedJun 2018 · 40 investors · BiotechnologyRule 506(b)
▶$88.1MraisedJun 2018 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Derek JantzExecutive Officer, Director
- Tony YaoDirector
- Matthew KaneExecutive Officer, Director
- Abid AnsariExecutive Officer
- Jeff SmithExecutive Officer
- Robert AdelmanDirector
- Offering amount
- $110M
- Amount sold
- $88.1M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25.6MraisedMay 2015 · 11 investors · BiotechnologyRule 506(b)
▶$25.6MraisedMay 2015 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JEFF SMITHExecutive Officer
- ROBERT ADELMANDirector
- DEREK JANTZExecutive Officer, Director
- MATTHEW KANEExecutive Officer, Director
- TODD MELBYExecutive Officer
- BEN AUSPITZDirector
- Offering amount
- $25.6M
- Amount sold
- $25.6M
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.